67 completed, 22 terminated, 8 unknown, 5 recruiting. 105 Phase 1, 31 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 105 | Completed 67, Terminated 22, Unknown 8, Recruiting 5, Withdrawn 2, Active not recruiting 1 |
| Phase 2 | 31 | Terminated 11, Completed 10, Unknown 7, Recruiting 3 |
Follow Sunitinib: new trials by email Literature Review of Sunitinib trials Research Report on Sunitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC Bicalutamide in combination with Sunitinib - Carcinoma, Renal Cell | Phase 1 / Phase 2 | Recruiting | State University of New York at Buffalo | 28 | 2024-10-01 | 2026-04-01 |
| Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate - Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 24 | 2024-08-14 | 2026-10-20 |
| The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions Aviga, capsules 50 mg / Sutent®, capsules 50 mg, Sutent®, capsules 50 mg / Aviga, capsules 50 mg - Bioequivalence | Phase 1 | Unknown | JLLC NatiVita | 22 | 2022-01-21 | 2022-02-01 |
| A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) Pimitespib, Imatinib, Sunitinib - Gastrointestinal Stromal Tumors | Phase 1 | Active not recruiting | Taiho Pharmaceutical Co., Ltd. | 78 | 2021-12-01 | 2026-01-20 |
| Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors Lenvatinib + Envafolimab, Sunitinib - Solid Tumors, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | 3D Medicines (Sichuan) Co., Ltd. | 170 | 2021-11-15 | 2026-03-25 |
| Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors Palbociclib, Sunitinib - Solid Tumors Refractory to Standard Therapy | Phase 1 / Phase 2 | Recruiting | Rabin Medical Center | 100 | 2021-10-21 | 2025-04-23 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Losartan + Sunitinib in Treatment of Osteosarcoma Losartan, Sunitinib - Osteosarcoma | Phase 1 | Recruiting | University of Colorado, Denver | 41 | 2019-08-26 | 2026-09-01 |
| A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma Abemaciclib, Sunitinib - Renal Cell Carcinoma Metastatic | Phase 1 | Terminated | Brown University | 3 | 2019-06-05 | 2024-06-25 |
| A Bioequivalence Study of Sunitinib Malate Capsules. Sunitinib malate capsules generic product, Sunitinib malate capsules reference product - Gastrointestinal Stromal Tumors, Renal Cell Carcinoma | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 24 | 2018-12-04 | 2023-04-10 |
| Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma Axitinib 1 MG, Sunitinib 5 MG, Pazopanib 5 MG - Recurrent Glioblastoma, Gliosarcoma | Phase 1 | Withdrawn | Center Trials & Treatment | 2018-07-17 | 2018-07-19 | |
| A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 1 | Completed | Graybug Vision | 32 | 2017-08-29 | 2019-12-20 |
| Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin - Soft Tissue Sarcoma, Bone Sarcoma | Phase 1 / Phase 2 | Completed | Grupo Espanol de Investigacion en Sarcomas | 197 | 2017-05-31 | 2024-08-13 |
| Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial Sunitinib, Isoquercetin, Placebo - Renal Cell Carcinoma, Kidney Cancer | Phase 1 / Phase 2 | Unknown | Consorzio Oncotech | 104 | 2016-11-01 | 2017-01-18 |
| Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dasatinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | OHSU Knight Cancer Institute | 7 | 2016-01-13 | 2020-05-26 |
| A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer BBI503, Capecitabine, Doxorubicin - Cancer | Phase 1 | Completed | Sumitomo Pharma America, Inc. | 165 | 2015-09-01 | 2023-11-14 |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Combination of varlilumab and sunitinib - Carcinoma, Renal Cell, Kidney Diseases | Phase 1 | Terminated | Celldex Therapeutics | 17 | 2015-05-01 | 2018-07-26 |
| Multiple Treatments for Ebola Virus Disease (EVD) Azithromycin, Sunitinib and Erlotinib, Atorvastatin and Irbesartan - Ebola Virus Disease | Phase 1 / Phase 2 | Unknown | Clinical Research Management, Inc. | 150 | 2015-04-01 | 2015-03-05 |
| CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors CGT9486, Pexidartinib, Sunitinib - Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | Completed | Cogent Biosciences, Inc. | 51 | 2015-03-06 | 2025-02-14 |
| Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) Sunitinib, Bevacizumab - Renal Cell Carcinoma | Phase 1 / Phase 2 | Unknown | King Faisal Specialist Hospital & Research Center | 77 | 2014-12-01 | 2018-08-10 |
Showing 20 of 105. Sign in to see all of them.
Carcinoma, Renal Cell (28) · Neoplasms (13) · Breast Neoplasms (11) · Kidney Neoplasms (7) · Gastrointestinal Stromal Tumors (6) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasm Metastasis (5) · Prostatic Neoplasms (5) · Leukemia, Myeloid, Acute (4) · Stomach Neoplasms (4) · Colorectal Neoplasms (3) · Glioblastoma (3) · Melanoma (3) · Pancreatic Neoplasms (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)
Pfizer (20) · National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (4) · Jonsson Comprehensive Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · OHSU Knight Cancer Institute (2) · Roswell Park Cancer Institute (2) · 3D Medicines (Sichuan) Co., Ltd. (1) · AEterna Zentaris (1) · Amgen (1) · Amsterdam UMC, location VUmc (1) · AstraZeneca (1) · Australasian Sarcoma Study Group (1) · Baylor Breast Care Center (1) · Bristol-Myers Squibb (1)
United States (69) · Canada (8) · Japan (5) · Italy (4) · Spain (4) · Australia (3) · China (3) · Netherlands (3) · Belgium (2) · Germany (2) · Singapore (2) · Belarus (1) · France (1) · Hong Kong (1) · Israel (1)
Glenn Liu (2) · Adam P Dicker, MD, PhD (1) · Adil Daud, M.D. (1) · Alba Rubio (1) · Andrew X. Zhu, MD (1) · Anne Traynor, MD (1) · Antonio Casado (1) · Arie Belldegrun, M.D. (1) · Aung Naing, MD (1) · Bartosz Chmielowski, MD (1)
PMID 19536893, PMID 20142724, PMID 20818327, PMID 20960028, PMID 21277078, PMID 22045104, PMID 22259028, PMID 22761653, PMID 23022045, PMID 23511559, PMID 23660867, PMID 23665950, PMID 23676418, PMID 23747347, PMID 24048627, PMID 24091982, PMID 24158411, PMID 24308791, PMID 24474568, PMID 24914044, PMID 25732163, PMID 25818407, PMID 26335224, PMID 26768569, PMID 27255678, PMID 30348216, PMID 30586316, PMID 31401903, PMID 31471313, PMID 31802410, PMID 32337094, PMID 32623479, PMID 33203665, PMID 33852135, PMID 34236401, PMID 36184621, PMID 39113428, PMID 39356980, PMID 39384801, PMID 39863139, PMID 41836677, PMID 7114936, PMID 8407399, PMID 9440743
P30CA014520 (2), U01CA062491 (2), U01CA062502 (2), 2015 (1), N01CM62201 (1), P30CA043703 (1), P30CA068485 (1), P30CA069533 (1), P30CA072720 (1), U01CA070095 (1), U01CA097452 (1), U01CA121947 (1), U01CA132194 (1), U10CA031946 (1), U10CA180821 (1)